Although the relationship of EGR-1 and PPARγ in the kidney has not been investigated yet, the PPARγ agonist rosiglitazone decreased skin fibrosis and EGR-1 levels in a mouse model of scleroderma [38]. Here, PPARG is linked to scleroderma.